Treats pain of osteoarthritis of the knee(s). ANDA 212506, held by Alembic. Diclofenac Sodium.
As of Nov 16, 2026, ANDA 212506 (Diclofenac Sodium), held by Alembic, was first approved by FDA on Nov 29, 2022, with 1 approved supplement and 0 published complete response letters.
Diclofenac sodium topical solution is indicated for the treatment of the pain of osteoarthritis of the knee(s).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 29, 2022 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Diclofenac Sodium2% · solution;topical | Diclofenac Sodium | Rx |
| Nov 21, 2024 | Supplement 3Labeling · Standard review | Approved | None posted |
| Nov 29, 2022 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters